Shopping Cart 0
Cart Subtotal
AED 0

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 22020

Details

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H1 2019, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 2, 43, 29, 1, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 2 and 1 molecules, respectively.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Introduction

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Overview

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics Assessment

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Companies Involved in Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Drug Profiles

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Discontinued Products

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AbbVie Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Actinium Pharmaceuticals Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by ADC Therapeutics SA, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Aduro BioTech Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Affimed GmbH, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AlfaSigma SpA, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Alissa Pharma, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Apollomics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Astellas Pharma Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AstraZeneca Plc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Aurigene Discovery Technologies Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by BeiGene Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Bristol-Myers Squibb Co, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Carrick Therapeutics Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celgene Corp, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cell Medica Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celldex Therapeutics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellectar Biosciences Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellectis SA, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celleron Therapeutics Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellestia Biotech AG, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellular Biomedicine Group Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celularity Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Checkpoint Therapeutics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Chipscreen Biosciences Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Constellation Pharmaceuticals Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Curis Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Eureka Therapeutics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Faron Pharmaceuticals Oy, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by FLX Bio Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Immunomedics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Incyte Corp, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Inhibrx LP, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Aduro BioTech Inc

Affimed GmbH

AlfaSigma SpA

Alissa Pharma

Anhui Anke Biotechnology (Group) Co Ltd

Apollomics Inc

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Biohaven Pharmaceutical Holding Company Ltd

Bristol-Myers Squibb Co

Carrick Therapeutics Ltd

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellular Biomedicine Group Inc

Celularity Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Constellation Pharmaceuticals Inc

Curis Inc

Eureka Therapeutics Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

FLX Bio Inc

Harbin Gloria Pharmaceuticals Co Ltd

Immunomedics Inc

Incyte Corp

Inhibrx LP

Jiangsu Hengrui Medicine Co Ltd

Kiromic Inc

Kite Pharma Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Miltenyi Biotec GmbH

Molecular Templates Inc

NantKwest Inc

NBE-Therapeutics AG

Recursion Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Rich Pharmaceuticals Inc

Sanofi

Seattle Genetics Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Group Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Stemline Therapeutics Inc

Syndax Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Taiwan Liposome Co Ltd

Trillium Therapeutics Inc

Company Profile

Company Profile Title

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H1 2019, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 2, 43, 29, 1, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 2 and 1 molecules, respectively.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Introduction

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Overview

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics Assessment

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Companies Involved in Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Drug Profiles

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Discontinued Products

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AbbVie Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Actinium Pharmaceuticals Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by ADC Therapeutics SA, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Aduro BioTech Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Affimed GmbH, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AlfaSigma SpA, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Alissa Pharma, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Apollomics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Astellas Pharma Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AstraZeneca Plc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Aurigene Discovery Technologies Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by BeiGene Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Bristol-Myers Squibb Co, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Carrick Therapeutics Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celgene Corp, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cell Medica Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celldex Therapeutics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellectar Biosciences Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellectis SA, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celleron Therapeutics Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellestia Biotech AG, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellular Biomedicine Group Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celularity Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Checkpoint Therapeutics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Chipscreen Biosciences Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Constellation Pharmaceuticals Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Curis Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Eureka Therapeutics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Faron Pharmaceuticals Oy, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by FLX Bio Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Immunomedics Inc, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Incyte Corp, H1 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Inhibrx LP, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Aduro BioTech Inc

Affimed GmbH

AlfaSigma SpA

Alissa Pharma

Anhui Anke Biotechnology (Group) Co Ltd

Apollomics Inc

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Biohaven Pharmaceutical Holding Company Ltd

Bristol-Myers Squibb Co

Carrick Therapeutics Ltd

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellular Biomedicine Group Inc

Celularity Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Constellation Pharmaceuticals Inc

Curis Inc

Eureka Therapeutics Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

FLX Bio Inc

Harbin Gloria Pharmaceuticals Co Ltd

Immunomedics Inc

Incyte Corp

Inhibrx LP

Jiangsu Hengrui Medicine Co Ltd

Kiromic Inc

Kite Pharma Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Miltenyi Biotec GmbH

Molecular Templates Inc

NantKwest Inc

NBE-Therapeutics AG

Recursion Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Rich Pharmaceuticals Inc

Sanofi

Seattle Genetics Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Group Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Stemline Therapeutics Inc

Syndax Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Taiwan Liposome Co Ltd

Trillium Therapeutics Inc